2018 Diarrhea Drug Development – Pipeline Analysis – ResearchAndMarkets.com

The “2018
Diarrhea Drug Development- Pipeline Analysis Report” report has
been added to ResearchAndMarkets.com’s offering.

With an estimated 1.5 million to 2 million people being affected
worldwide, Diarrhea is the most catastrophic disease causing morbidity
among children. Developing and poor countries are most susceptible to
diarrhea.

To assist investigators and funding and regulatory organizations, the
publisher has come up with a comprehensive report on Diarrhea pipeline.
The report provides insights into different therapeutic candidates in
preclinical, research, discovery, NDA/IND, pre registration, phase 1,
phase 2, and phase 3 trials). Drugs under development directly and
through combination with other drugs are also included.

Current status, developmental phase, participating companies and
entities, recent developments, orphan drug/ fast track/ other
designations, drug class are provided for each Diarrhea pipeline
product. Mechanism of Action and the target area of the pipeline product
are also provided. Further, clinical and preclinical trials along with
results of the trials are also included in the report.

In addition to complete details of each product, the report provides key
trends in Diarrhea pipeline studies. The products under development are
categorized according to their development phase, mechanism and company
to provide detailed insights into the type of drugs being developed and
the stages of development.

Key Topics Covered

1 Diarrhea Pipeline Analysis

2 Diarrhea – Company Wise Pipeline Analysis

3 Diarrhea R&D Pipeline Snapshots

4 Recent Developments in Diarrhea Pipeline

5 Appendix

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/research/gf9l7v/2018_diarrhea?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180712005452/en/

Leave a Comment